{
  "drug_name": "Lefamulin",
  "tradename": "Xenleta",
  "usage_and_dosing": {
    "general_info": [
      "Lefamulin, a pleuromutilin antibacterial, is approved for the IV and oral treatment of adults with community-acquired pneumonia (CAP) caused by susceptible strains of S. pneumoniae, S. aureus (MSSA), H. influenzae, L. pneumophila, M. pneumoniae, and C. pneumoniae.",
      "Although active in vitro, Lefamulin is not approved for CAP caused by resistant Staph. aureus (MRSA) due to limited clinical data.",
      "No in vitro activity vs Enterobacteriaceae or Ps.aeruginosa.",
      "As effective as moxifloxacin in controlled clinical trials of community-acquired bacterial pneumonia: Clin Infect Dis 2019;69:1856",
      "Pleuromutilins inhibit bacterial protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thereby preventing the binding of tRNA for peptide transfer.",
      "Cautions",
      "Animal studies suggest lefamulin may cause harm if administered to a pregnant woman. Verify pregnancy status in females of reproductive potential before using. Safety in lactation is unknown; breastfeeding women should pump and discard milk for the duration of treatment and for two days after the final dose.",
      "Numerous drug interactions (see chart below, not all-inclusive). Lefamulin metabolized by CYP3A4 and hence can interact with drugs that are inhibitors or inducers of CYP3A4 or drugs that are substrates of CYP34A enzymes",
      "Lefamulin may prolong the QTc interval. Avoid concomitant use with other drugs that can prolong the QTc interval and thereby increase the risk of ventricular arrhythmias.",
      "Reference: Med Lett Drugs Ther 2019;61:145"
    ],
    "adult_dose": [
      {
        "route": "Oral",
        "recommended_dose": "600 mg po q12h",
        "treatment_duration": "5 days"
      },
      {
        "route": "Intravenous",
        "recommended_dose": "150 mg IV (over 60 min) q12h",
        "treatment_duration": "5-7 days"
      }
    ],
    "pediatric_dose": {
      "age": ">28 Days",
      "safety_and_efficacy": "not established"
    },
    "renal_adjustment": {
      "half_life_hrs_renal_function_normal": 8,
      "half_life_hrs_esrd": "Unchanged",
      "dose_renal_function_normal": [
        "600 mg po q12h",
        "150 mg IV q12h"
      ],
      "crcl_or_egfr": "No dosage adjustment for renal impairment",
      "hemodialysis": "No dosage adjustment",
      "capd": "No data",
      "crrt": "No data",
      "sled": "No data"
    },
    "hepatic_adjustment": {
      "mild_impairment_child_pugh_class_a": {
        "injection": "no dosage adjustment",
        "tablets": "no dosage adjustment"
      },
      "moderate_impairment_child_pugh_class_b": {
        "injection": "no dosage adjustment",
        "tablets": "no data, not recommended"
      },
      "severe_impairment_child_pugh_class_c": {
        "injection": "dosage to 150 mg q24h",
        "tablets": "no data, no recommended"
      }
    }
  },
  "adverse_effects": [
    "Gastrointestinal (nausea, vomiting, diarrhea, C. difficile-associated diarrhea).",
    "In the phase 3 FDA registration trial vs moxifloxacin for CAP, the incidence of GI side effects was 17.9% in the Lefamulin patients vs 7.6% in the moxifloxacin patients: JAMA.2019;322:1661.",
    "Headache, insomnia.",
    "Injection site reactions.",
    "Elevation in hepatic transaminases.",
    "QT-interval prolongation."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "May cause fetal harm, based on toxicity in animal studies",
    "use_during_lactation": "Avoid use; pump and discard milk for tx duration and two days post."
  },
  "antimicrobial_spectrum": {
    "preferred": [],
    "alternative": [
      "S. pneumoniae",
      "H. influenzae",
      "M. pneumoniae, C. pneumoniae, and Legionella pneumophila",
      "MSSA",
      "MRSA",
      "M. catarrhalis",
      "Other streptococcal species",
      "H. parainfluenzae",
      "Active vs STD pathogens, including Chlamydia trachomatis, Mycoplasma genitalium, and Neisseria gonorrhoeae",
      "No activity vs gram-negative enteric bacilli or Ps. aeruginosa"
    ]
  },
  "pharmacology": {
    "pk_pd_index": "24-hr AUC/MIC",
    "pharmaceutical_preparations": [
      "Tab (600 mg)",
      "Injection"
    ],
    "oral_absorption_percent": 25,
    "tmax_hr": "po: 0.88-2.0",
    "peak_serum_conc_mcg_ml": {
      "iv": "3.6 (150 mg IV q12h, SS)",
      "po": "2.24 (600 mg po q12h, SS)"
    },
    "protein_binding_percent": "94.8-97.1",
    "volume_of_distribution_vd": "86.1 L (Vss)",
    "avg_serum_t1_2_hr": 8,
    "elimination": "Metabolized",
    "auc_mcg_hr_ml": {
      "iv": "28.6 (150 mg IV q12h, 0-24 hr)",
      "po": "32.7 (600 mg po q12h, 0-24 hr)"
    }
  },
  "enzyme_transporter_mediated_interactions": {
    "cyp450s_that_drug_is_a_substrate_for": "CYP3A4",
    "cyp450s_inhibited_by_drug": "CYP3A4",
    "impact_on_serum_drug_concentrations": "↑"
  },
  "major_drug_interactions": [
    {
      "drug": "Alprazolam",
      "effect_on_concentration_or_other": "↑ alprazolam",
      "suggested_management": "Monitor, adjust dosa"
    },
    {
      "drug": "Amiodarone",
      "effect_on_concentration_or_other": "↑ amiodarone, ↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Antipsychotics",
      "effect_on_concentration_or_other": "↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Diltiazem",
      "effect_on_concentration_or_other": "↑ diltiazem",
      "suggested_management": "Monitor, adjust dosa"
    },
    {
      "drug": "Fluoroquinolones",
      "effect_on_concentration_or_other": "↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Ketoconazole",
      "effect_on_concentration_or_other": "↑ lefamulin",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Macrolides",
      "effect_on_concentration_or_other": "↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Midazolam (po)",
      "effect_on_concentration_or_other": "↑ midazolam",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Pimozide",
      "effect_on_concentration_or_other": "↑ pimozide, ↑ QT interval",
      "suggested_management": "Contraindicated"
    },
    {
      "drug": "Procainamide",
      "effect_on_concentration_or_other": "↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Quinidine",
      "effect_on_concentration_or_other": "↑ quinidine, ↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Rifampin",
      "effect_on_concentration_or_other": "↓ lefamulin",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Simvastatin",
      "effect_on_concentration_or_other": "↑ simvastatin",
      "suggested_management": "Monitor, adjust dosa"
    },
    {
      "drug": "Sotalol",
      "effect_on_concentration_or_other": "↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Tricyclic antidepressants",
      "effect_on_concentration_or_other": "↑ QT interval",
      "suggested_management": "Avoid co-administrat"
    },
    {
      "drug": "Vardenafil",
      "effect_on_concentration_or_other": "↑ vardenafil",
      "suggested_management": "Monitor, adjust dosa"
    },
    {
      "drug": "Verapamil",
      "effect_on_concentration_or_other": "↑ verapamil",
      "suggested_management": "Monitor, adjust dosa"
    }
  ]
}